Effective treatment approaches in a pandemic, such as coronavirus disease 2019 (COVID‐19), hinge on expeditious identification of sound dosing strategies. Informed by experience with the US Food and Drug Administration (FDA) Animal Rule, this commentary illustrates a framework for leveraging and integrating clinical pharmacology information for dose selection to treat novel infections in a public health emergency setting.
展开▼